Opendata, web and dolomites


New vaccine for a paradigm shift in Brucellosis

Total Cost €


EC-Contrib. €






 BGV1 project word cloud

Explore the words cloud of the BGV1 project. It provides you a very rough idea of what is the project "BGV1" about.

forecast    africa    costly    zoonotic    prohibited    ranked    lactating    benefits    anywhere    bgv1    trading    interfering    people    restricted    diagnostic    estimate    programs    patented    animal    accounting    latam    techniques    rational    endemic    profits    first    animals    bioterrorism    farmers    reaching    eradication    disease    02m    global    infect    86    mediterranean    virulence    inconveniences    radical    income    devastating    29m    3bn    58    treatments    candidate    normally    paradigm    pregnant    economic    500    13m    generating    accumulated    revenue    vaccines    travelling    world    prevalence    exists    outbreaks    livestock    time    tam    recommended    residual    net    brucellosis    appropriate    human    vaccine    threat    place    international    losses    mass    tool    regions    asia    preventing    76bn    conservative    causes    92    simplifies    hospital    countries    standard    prevalent    slaughter    15    projection    requiring    check    ups    vaccination    tests    annually    infection    humans    consistently    shift    compensation    infected   

Project "BGV1" data sheet

The following table provides information about the project.


Organization address
address: PLAZA LAMITURRI, 10, 1 A
postcode: 31192
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-05-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BRUCELLA GREEN VAC SL ES (MUTILVA) coordinator 50˙000.00


 Project objective

Brucellosis is consistently ranked as the world’s most common and widespread zoonotic disease, meaning that it normally exists in animals but it can also infect humans. In livestock, it causes devastating production losses in low-income countries accounting in more than €3bn per year. In humans, there are 500,000 new cases annually requiring long-term hospital treatments. Brucellosis is endemic in most Asia, Africa and LATAM and is prevalent in the EU Mediterranean regions. Also, outbreaks may take place anywhere in a global world with international trading, people travelling all around the world and potential threat of bioterrorism.

Since human vaccines are not available, the most rational approach for preventing human brucellosis is the control and eradication of infection in animals. Animal vaccines are an essential tool, but existing vaccines own some inconveniences, such as residual virulence, complex management systems and costly diagnostic techniques that are not appropriate for developing countries; in Europe, control programs are based in tests for animal check-ups and compensation to farmers for slaughter of the infected animals, with vaccination prohibited or highly restricted to areas with higher prevalence of Brucellosis. These inconveniences recommended the development of new candidate vaccines.

We are developing BGV1, a patented vaccine that has the potential of allowing, for the first time, mass vaccination of any animal at any time (including pregnant and lactating animals), which is a radical paradigm shift in Brucellosis control and eradication. It also simplifies existing vaccine management systems as it can be used without interfering standard diagnostic techniques. In our 5-year forecast, we estimate accumulated revenue and net profits of €58.29m and €15.13m, a conservative projection by just reaching 86.02m animals that represent only 3.92% of our TAM, generating 1.76bn economic benefits to our users.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BGV1" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BGV1" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

Totem Spoon (2019)

Interactive Digital Signage with emotional intelligence for smart cities

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More